101 results
8-K
EX-3.1
ZVRA
Zevra Therapeutics Inc
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
definitions shall apply:
(1) The term “proceeding” shall be broadly construed and shall include, without limitation, the investigation, preparation
8-K
EX-4.1
ZVRA
Zevra Therapeutics Inc
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
incurred with the investigation, preparation and prosecution of such action or proceeding.
f) Restrictions. The Holder acknowledges that the Warrant
8-K
EX-99.2
ZVRA
Zevra Therapeutics Inc
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
exercise of the Pre-Funded Warrants.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal … investigation or partial proceeding, such as a deposition), whether commenced or threatened.
“Prospectus” means the final prospectus filed
8-K
EX-10.1
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
also shall cooperate fully with Company in connection with any investigation or review by any federal, state or local regulatory authority as any … such investigation or review relates, to events or occurrences that transpired while Executive was employed by Company. Notwithstanding anything
424B3
rmwiqsh6khzr8lxvw
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
f5559jpicv4ytsvtbi
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
EX-5.1
rjbn1 udn
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
S-4
spj5w050r xx8dg7
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
ca4j5sjwb xxi8
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-10.4
k18bb8 264im
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-2.1
m31fn x15e6my7ujqo
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.1
39g1 8hbepcp
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.1
kx0i4
8 May 23
Departure of Directors or Certain Officers
7:44am
8-K
EX-10.1
62hhjv8pcm1147m is
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
424B3
eihcur
10 Nov 21
Prospectus supplement
5:19pm
424B3
0pv65c2dc19pyv5yfx
10 Nov 21
Prospectus supplement
5:15pm
8-K
EX-10.1
0q0ttvv6lmrc6r355
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm